CDK5R1 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CDK5R1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CDK5R1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CDK5R1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=CDK5R1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
CDK5R1 encodes p35, the primary neuronal-specific regulatory subunit of cyclin-dependent kinase 5 (CDK5). The p35/CDK5 complex is a critical kinase in the central nervous system (CNS), regulating neuronal development, synaptic plasticity, and various cellular functions essential for cognitive function. Dysregulation of the p35/CDK5 pathway, particularly through proteolytic cleavage of p35 to the truncated p25 fragment, has emerged as a key mechanism in the pathogenesis of several neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis). [@cdk2004] [@generation2004]
The cleavage of p35 to p25 represents a critical switch that converts the physiological p35/CDK5 complex into a hyperactive p25/CDK5 complex. This conversion leads to aberrant phosphorylation of CDK5 substrates, including [tau protein](/proteins/tau), resulting in neurofibrillary tangle formation, synaptic dysfunction, and ultimately, neuronal death. Understanding the mechanisms governing p35 regulation and p25 generation has become a major focus for developing disease-modifying therapies for neurodegenerative conditions. [@generation2004] [@chen2018]
Gene And Protein Context
- Symbol: CDK5R1
- Full name: Cyclin-Dependent Kinase 5 Regulatory Subunit 1
- Chromosomal locus: 17q11.2
- NCBI Gene ID: [8851](https://www.ncbi.nlm.nih.gov/gene/8851)
- Ensembl ID: [ENSG00000108395](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108395)
- UniProt ID: [Q15078](https://www.uniprot.org/uniprot/Q15078)
- Protein molecular weight: ~35 kDa (p35), 25 kDa (p25)
- Expression: Neuron-specific; high expression in cortex, hippocampus, cerebellum, basal ganglia
The p35 protein (350 amino acids) is synthesized in neurons and localizes primarily to the plasma membrane through an N-terminal myristoylation site. This membrane association is important for the spatial regulation of CDK5 activity within neurons. The protein contains a CDK5-binding domain in its C-terminal region that is necessary for kinase activation. Upon proteolytic cleavage by calcium-activated calpains, p35 is cleaved to generate p25 (residues 98-307) and a p10 fragment (residues 1-98). The p25 fragment lacks the myristoylation site, leading to its accumulation in the cytosol and prolonged activation of CDK5. [@generation2004] [@chen2018]
Molecular Functions In The Nervous System
CDK5 Activation and Regulation
p35 serves as the essential neuronal activator of CDK5, a proline-directed serine/threonine kinase. Unlike other cyclin-dependent kinases, CDK5 does not require canonical cyclin binding for activation; instead, it is activated by binding to p35 (or the related p39 protein encoded by CDK5R2). The p35/CDK5 complex phosphorylates numerous substrates involved in:
Cytoskeletal proteins: Tau, MAP1B, neurofilaments
Synaptic proteins: Synaptic vesicles, NMDA/AMPA receptor subunits
Transcription factors: CREB, NF-κB, p53
Signal transduction: Various kinases and phosphatasesThe activity of the p35/CDK5 complex is tightly regulated through multiple mechanisms, including protein synthesis, degradation, phosphorylation, and proteolytic cleavage. This complex regulation ensures proper temporal and spatial control of CDK5 activity during neuronal development and in the adult brain. [@fischer2017]
Neuronal Development
During CNS development, the p35/CDK5 complex plays essential roles in:
- Neuronal migration: Phosphorylation of substrates that regulate cytoskeletal dynamics necessary for radial and tangential migration
- Axon guidance: Modulation of growth cone dynamics and guidance cue responses
- Synaptogenesis: Regulation of synaptic protein localization and assembly
- Cell cycle exit: Contributing to the irreversible post-mitotic state of neurons
Mouse knockout studies demonstrate that CDK5R1 deletion results in perinatal lethality with severe cortical lamination defects, highlighting the essential nature of this gene during development. [@su2018]
Synaptic Plasticity and Memory
In the adult brain, p35/CDK5 continues to play crucial roles in synaptic function and plasticity:
- Long-term potentiation (LTP): CDK5 activity is required for stable LTP, partly through phosphorylation of NMDA and AMPA receptor subunits
- Long-term depression (LTD): CDK5 regulates endocytosis of AMPA receptors during LTD
- Learning and memory: Conditional knockout of CDK5 in excitatory neurons enhances memory formation, while p25 overexpression impairs cognition
The role of CDK5 in memory consolidation is particularly interesting, as it appears to act as a negative regulator under certain conditions, with CDK5 activity increasing after learning to constrain memory strength—a potential mechanism to prevent overconsolidation. [@fischer2017] [@giese2015]
Cytoskeletal Regulation
p35/CDK5 phosphorylates multiple cytoskeletal proteins essential for neuronal structure and transport:
- Tau: Phosphorylation at multiple sites (Ser202, Thr205, Ser396, etc.) regulates microtubule binding
- MAP1B: Phosphorylation regulates microtubule dynamics during development
- Neurofilaments: Phosphorylation maintains neurofilament stability and transport
- Dynamin-1: Phosphorylation regulates synaptic vesicle endocytosis
Dysregulation of these phosphorylation events contributes to cytoskeletal disruption, transport deficits, and ultimately, neuronal dysfunction in neurodegeneration. [@shukla2019]
Role In Neurodegeneration
Alzheimer's Disease
The involvement of CDK5R1/CDK5 in AD is multifaceted and represents one of the most well-characterized pathogenic mechanisms:
p35 to p25 Cleavage
In AD brains, p35 is abnormally cleaved by calcium-activated calpains to generate the truncated p25 fragment. This cleavage is thought to occur as a result of:
Calcium dysregulation: AD-associated calcium dyshomeostasis activates calpains
Oxidative stress: Oxidative modifications to p35 may increase its susceptibility to cleavage
Age-related changes: Calpain activation increases with normal agingThe p25 fragment has a longer half-life than p35, leading to accumulation and prolonged CDK5 activation. Additionally, p25 lacks the membrane-targeting myristoylation site, resulting in mislocalized kinase activity throughout the neuron. [@generation2004] [@chen2018]
Tau Hyperphosphorylation
Hyperactive p25/CDK5 phosphorylates tau at multiple sites that promote its aggregation into neurofibrillary tangles:
- Ser202/Thr205: AD-relevant phosphorylation sites found in early pretangles
- Ser396: Critical for tangle formation
- Thr231: conformational change facilitating aggregation
This phosphorylation disrupts tau's ability to bind microtubules and promotes its self-assembly into paired helical filaments. Importantly, p25/CDK5 can also phosphorylate kinases (GSK-3β) and inhibit phosphatases (PP2A) that further exacerbate tau pathology. [@cdk2004] [@zhang2021]
Synaptic Dysfunction
p25/CDK5 hyperactivity contributes to synaptic loss through:
AMPA receptor trafficking: Abnormal phosphorylation affects synaptic plasticity mechanisms
Presynaptic proteins: Impaired vesicle release and recycling
Dendritic spine morphology: Reduced spine density and altered spine shape
NMDA receptor dysfunction: Altered receptor trafficking and signalingThe synaptic effects of p25 accumulation occur early in disease and likely contribute to the cognitive decline that precedes overt neuron loss. [@cdka2004] [@fischer2017]
Parkinson's Disease
In PD, CDK5 participates in several pathogenic mechanisms:
LRRK2 Phosphorylation
CDK5 phosphorylates leucine-rich repeat kinase 2 (LRRK2), the most common genetic cause of familial PD:
- CDK5 phosphorylates LRRK2 at Ser910 and Ser935, regulating its cytosolic localization
- Pathogenic LRRK2 mutations may alter CDK5-mediated regulation
- This interaction connects two major PD pathways
Dopaminergic Neuron Vulnerability
CDK5 activity is particularly high in dopaminergic neurons of the substantia nigra:
- MPTP and other PD toxins increase CDK5 activity
- CDK5 inhibition protects against toxin-induced dopaminergic death
- p25 accumulation is observed in PD brains
Alpha-Synuclein Interplay
CDK5 can phosphorylate alpha-synuclein at Ser129, a modification found in Lewy bodies:
- Phosphorylated alpha-synuclein shows enhanced aggregation
- CDK5-mediated phosphorylation may link the two major proteinopathies in PD
These findings position CDK5 as a therapeutic target in PD, though the complexity of its physiological functions requires careful approach. [@cdkb2007] [@lrrk2009] [@liu2016] [@mendonca2020]
Amyotrophic Lateral Sclerosis
In ALS, CDK5 dysregulation contributes to motor neuron pathology:
TDP-43 phosphorylation: CDK5 can phosphorylate TDP-43, a major protein in ALS pathology
Cytoskeletal disruption: Enhanced phosphorylation of neurofilaments
Axonal transport deficits: Impaired organelle trafficking
Muscle denervation: Synaptic dysfunction at the neuromuscular junctionMotor neurons appear particularly vulnerable to CDK5 dysregulation due to their large size and dependence on cytoskeletal integrity. [@cdkc2010]
Other Neurodegenerative Conditions
Frontotemporal Dementia
In FTD and related tauopathies, CDK5-mediated tau phosphorylation contributes to pathology:
- Elevated p25 levels in some FTD cases
- Tau phosphorylation at CDK5 sites correlates with disease severity
- Interaction with other FTD-linked proteins
Huntington's Disease
CDK5 is implicated in HD through:
- Abnormal regulation in striatal neurons
- Interaction with mutant huntingtin protein
- Contribution to transcriptional dysregulation
Multiple Sclerosis
Emerging evidence suggests CDK5 involvement in demyelinating diseases:
- Oligodendrocyte differentiation regulation
- Myelin protein phosphorylation
- Axonal degeneration mechanisms
Disease Associations And Translational Relevance
Therapeutic Strategies
Given the strong evidence for CDK5 dysregulation in neurodegeneration, several therapeutic approaches are being explored:
CDK5 Inhibitors
Roscovitine (Seliciclib): The most advanced CDK5 inhibitor, originally developed for cancer, shows neuroprotective effects in AD and PD models. Currently in clinical trials for various indications. [@dwyer2016] [@qu2019]
Alogliptin: A DPP-4 inhibitor with off-target CDK5 modulatory activity, approved for diabetes; being investigated for neurodegenerative applications
Specific p25 inhibitors: Targeting the p25/CDK5 complex specifically to avoid interfering with physiological p35/CDK5 functionCalpain Inhibitors
Since calpain-mediated p35 cleavage generates p25, calpain inhibitors represent an indirect approach:
- MDL-28170: Shown to reduce p25 generation and protect neurons
- Natural compounds: Certain flavonoids and polyphenols with calpain-inhibitory activity
p35-Targeting Approaches
Gene therapy: Viral delivery of p35 or its derivatives to restore proper CDK5 regulation
Peptide inhibitors: Cell-permeable peptides that block p25-CDK5 interaction
Allosteric modulators: Compounds that modulate the p35-CDK5 interfaceBiomarker Potential
Changes in p35/p25 ratios or CDK5 activity may serve as biomarkers:
- CSF p25 levels correlate with disease severity in some studies
- Peripheral blood mononuclear cell CDK5 activity as a surrogate marker
- Further validation needed for clinical implementation
Challenges in Therapeutic Development
Physiological functions: CDK5 has essential roles in learning, memory, and neuronal health
Cell-type specificity: Effects differ between neuronal subtypes
BBB penetration: Many CDK5 inhibitors have limited brain access
Narrow therapeutic window: Balance between efficacy and toxicityExperimental Models And Methods
Genetic models: p35 knockout mice (lethal), p25 transgenic mice (AD-like pathology), conditional p25 mice (reversible phenotype) [@kanungo2015]
Viral vectors: AAV-mediated p25 expression to model neurodegeneration
Inhibitor studies: Roscovitine and derivatives in various disease models
Cell culture: Primary neurons, iPSC-derived neurons for mechanistic studies
Phosphoproteomics: Global mapping of CDK5 substrates in disease statesResearch Gaps And Future Directions
Temporal dynamics: When does p25 accumulation begin relative to clinical symptoms?
Cell-type specificity: What makes certain neurons more vulnerable to p25/CDK5 dysregulation?
Biomarker validation: Can p25 or CDK5 activity serve as a clinical biomarker?
Combination therapies: How might CDK5-targeted approaches combine with anti-amyloid or anti-tau strategies?
Safety considerations: How can we preserve physiological CDK5 function while targeting pathological p25 activity?See Also
- [CDK5 Protein — Cyclin-Dependent Kinase 5](/proteins/cdk5-protein)
- [Tau Protein in Alzheimer's Disease](/proteins/tau)
- [LRRK2 in Parkinson's Disease](/genes/lrrk2)
- [TDP-43 in ALS](/proteins/tdp-43)
- [Tau Hyperphosphorylation Pathway](/mechanisms/tau-hyperphosphorylation-pathway)
References
[Lee et al., CDK5 in tau pathogenesis (2004)](https://pubmed.ncbi.nlm.nih.gov/14597658/)
[Patrick et al., p25 generation in AD brain (2004)](https://pubmed.ncbi.nlm.nih.gov/14749363/)
[Huang et al., CDK5 and synaptic plasticity (2004)](https://pubmed.ncbi.nlm.nih.gov/15162105/)
[Smith et al., CDK5 in PD models (2007)](https://pubmed.ncbi.nlm.nih.gov/17452840/)
[Greggio et al., LRRK2 phosphorylation by CDK5 (2009)](https://pubmed.ncbi.nlm.nih.gov/19794439/)
[Cruz et al., CDK5 in ALS (2010)](https://pubmed.ncbi.nlm.nih.gov/20665475/)
[Rack et al., CDK5 in Huntington's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19855041/)
[Alonso et al., CDK5 in frontotemporal dementia (2010)](https://pubmed.ncbi.nlm.nih.gov/20629637/)
[Zhang et al., CDK5-mediated tau phosphorylation (2021)](https://pubmed.ncbi.nlm.nih.gov/34104218/)
[Chen et al., Calpain-mediated p35 cleavage (2018)](https://pubmed.ncbi.nlm.nih.gov/30531792/)
[Qu et al., CDK5 inhibitors for AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31364171/)
[Fischer et al., CDK5/p35 signaling in synaptic plasticity (2017)](https://pubmed.ncbi.nlm.nih.gov/28647657/)
[Kanungo et al., p35 transgenic models (2015)](https://pubmed.ncbi.nlm.nih.gov/25872432/)
[Liu et al., CDK5 in PD pathogenesis (2016)](https://pubmed.ncbi.nlm.nih.gov/27550158/)
[Mendonca et al., CDK5 and alpha-synuclein (2020)](https://pubmed.ncbi.nlm.nih.gov/32621397/)
[Su et al., CDK5 substrates in neuronal development (2018)](https://pubmed.ncbi.nlm.nih.gov/29544312/)
[Dwyer et al., Roscovitine in AD models (2016)](https://pubmed.ncbi.nlm.nih.gov/27185314/)
[Giese et al., Memory consolidation and CDK5 (2015)](https://pubmed.ncbi.nlm.nih.gov/26120963/)
[Shukla et al., CDK5 in cytoskeletal dynamics (2019)](https://pubmed.ncbi.nlm.nih.gov/31049873/)
[Petralla et al., CDK5 and neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32791964/)